Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128795) titled 'A clinical study of vitamin K2 supplementation for the prevention of immune-related adverse events in patients with NSCLC treated with immune checkpoint inhibitors combined with first-line chemotherapy' on July 26.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Xuzhou Central Hospital

Condition: Lung cancer

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2024-08-30

Target Sample Size: Intervention group:50;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=241815

Disclaimer: Curated by HT Syndication....